Genmab: Quality Slips, Valuation Under Pressure
Genmab trades at a discount for clear reasons: margin and capital returns are both slipping. The company’s focus on antibody therapies makes it vulnerable to innovation cycles. For this stock, a 5.2% ROIC just isn’t enough. Only a sustained turnaround in both metrics would change the market’s stance.
Published by AssetNext · 2026-06-04
| Date | Signal | Peer score | Drawdown | 21d vs sector |
|---|---|---|---|---|
| 2026-06-08 | Profile and price weak | 32 | -28.4% | -31.3% |
| 2026-06-02 | Profile and price weak | 32 | -31.4% | -38.2% |
| 2026-05-27 | Profile and price weak | 34 | -23.4% | -19.0% |
Break down GMAB.CO's structural position across all peer dimensions with the interactive app.